Study design.
MAY, INFECTIOUS, CORONAVIRUS
This study was a double-blind, randomized, placebo-controlled, multicenter, phase 2 clinical trial in patients with mild to moderate COVID-19. Enrollment of participants began in February 2021 and ended in May 2021. There were 21 study sites, all in South Korea. This clinical trial was planned and recruited COVID-19 patients in South Korea in accordance with the quarantine guidelines, “Coronavirus Infectious Disease-19 Response Guidelines (10-2 edition)” (The study protocol was approved by the institutional review board at each study site. Written informed consent was obtained from all patients for participation in this study. This trial was registered with ClinicalTrials.gov (registration no. NCT04521296), and the study protocol can be seen in the supplemental material.